Back to Search
Start Over
Off-Label Use of Letermovir as Preemptive Anti-Cytomegalovirus Therapy in a Pediatric Allogeneic Peripheral Blood Stem Cell Transplant.
- Source :
- Infection & Drug Resistance; Mar2021, Vol. 14, p1185-1190, 6p
- Publication Year :
- 2021
-
Abstract
- Despite the effectiveness of the currently available antiviral drugs in treating cytomegalovirus (CMV) infection, high rates of adverse effects are associated with their use. Moreover, a problem of increasing importance is the emergence of drug-resistant CMV infection. Here, we describe the first case of off-label use of letermovir (LMV) as preemptive antiviral therapy, in a pediatric allogeneic peripheral blood stem cell transplant recipient with ganciclovir-resistant CMV infection who was intolerant to foscarnet and unable to achieve viral clearance after seven doses of cidofovir. After the administration of LMV, a gradual reduction in viral load was observed and within 6 weeks of LMV treatment, after more than 6 months of positive CMV-DNAemia, the patient cleared the infection. No adverse effects associated with LMV were observed during treatment. In this pediatric study case, the off-label use of LMV for the treatment of CMV infection has been well tolerated and proved to be effective in leading to the suppression of viral replication. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 11786973
- Volume :
- 14
- Database :
- Complementary Index
- Journal :
- Infection & Drug Resistance
- Publication Type :
- Academic Journal
- Accession number :
- 150586147
- Full Text :
- https://doi.org/10.2147/IDR.S296927